GenMark Sees 80% Q1 Revenue Boost on Covid-19 Tests

After the close on Tuesday, GenMark (GNMK) preannounced above-consensus 1Q20 revenue given tailwinds from COVID-19 testing. The molecular diagnostics company is now expecting first quarter revenue of about $38.7 million, up about 80% year-over-year.It also raised its 2020 revenue guidance to $112- $122 million, up from the previously estimated $100- $110 million.“Our sample-to-answer test enables healthcare providers to determine if a patient has COVID-19 in under two hours and is a critical diagnostic solution for hospitals. I’m extremely proud of our team’s hard work throughout this crisis as we continue to work at maximum capacity to provide our ePlex SARS-CoV-2 …read more

Source:: Yahoo Finance


Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.